2020 World Science and Technology Development: The global "big test" of the new crown

li Shan
a German researcher, found that neuroclear protein 1 (NRP1) is a factor that promotes the entry of new coronavirus into cells. The Magp Institute of Biophysics has found that an inhibitor can work together to fight the new coronavirus, not only blocking the replication of the new coronavirus, but also enhancing the body's immune response to the new coronavirus. Using virtual screening techniques to find active ingredients that inhibit the new coronavirus, the Ulysses Research Center eventually screened about 10,000 molecules, of which reloxifen showed strong activity in laboratory trials., our correspondent in the United States, said that the united
has now become the world's worst outbreak of new crown pneumonia. The Trump administration withdrew from the World Health Organization and refused to participate in the New Crown Vaccine Implementation Program.
and U.S. scientists have become an important force in the treatment and vaccine development of the new coronary pneumonia. The New Crown Outbreak High Performance Computing Alliance, led by IBM and the Department of Energy, brings together high-performance computing resources from governments, businesses, and academia to become an important driver of scientific research on new crown outbreaks and viruses.
A new method developed by the University of California, Santa Cruz to prepare a probe library for "tumucogen analysis" could play a role in immunoreactive research; New Coronary Pneumonia Candidate Drugs; Personalized Risk Prediction Models developed by the Cleveland Clinic that predict the likelihood of patients testing positive can be used as an aid to doctors' decision-making; and the Scripps Institute has discovered a gene that strongly reacts to the new coronavirus, providing ideas for designing effective vaccines.
point out that cooperation between Chinese and American scientists has played an important role in the study of the new coronavirus. An experimental AI tool developed in collaboration with researchers from the two countries can accurately predict the direction of a patient's condition and provide reference for doctors' decision-making, and their analysis of early cases and their close contacts in Shenzhen, China, provides basic evidence for predicting the impact of the new coronavirus, assessing control measures and guiding the global response.
outbreak, countries have placed their hopes of success in fighting the disease on the development of a new crown vaccine, as has the United States. Several vaccine research and development institutions, such as Modner and Pfizer, are scrambling to actively promote relevant experimental research. On March 16th the first phase I clinical trial of a candidate vaccine in the United States officially began, and so far, several Phase III clinical trial results have been published showing that both Pfizer and Modner's vaccines have shown good results, with an efficiency of more than 90%.. Li Hongze, our correspondent in France
France has a worldwide reputation for vaccine research and development capabilities, and the French government sees vaccines as the key to victory in the fight against the new crown pneumonia epidemic. Pasteur Research Institute, which has a global research and development network, and Sanofi, a multinational pharmaceutical group, are the two main players in French vaccine research and development, but the development of the new crown vaccine has been relatively slow compared to the United States.
Sanofi is one of the few vaccine companies in the world that is developing two technology routes. Its first vaccine in the study is a recombinant protein vaccine developed in cooperation with GlaxoSmithKline (GSK) in the United Kingdom, based on Sanofi's seasonal influenza vaccine technology platform, provided by GSK. Sanofi reached a pre-order agreement with the European Union in September 2020 for 300 million doses of the vaccine, but in the latest tests, the vaccine has underperformed people over 50 and still needs to be improved and more clinical trials conducted. Sanofi's new mRNA vaccine is expected to be available in the fourth quarter of 2021.
new crown vaccine based on measles vaccine technology developed by the Pasteur Institute in France and pharmaceutical giant Merck is now in Phase I human clinical trials.
In the treatment of neo-crown pneumonia, a team of European scientists led by the University Hospital of Sakre in Paris, France, found that most newborns were infected with neo-coronavirus due to environmental exposure, and that 30 per cent of reported cases may have been contracted from mothers. Researchers at the Paris Public Hospitals Group and the University of Paris-Sakre, who conducted studies of patients hospitalized for neo-coronary pneumonia, showed that asthma sufferers were not at increased risk of contracting neo-crown pneumonia.' correspondent in Brazil, Deng Guoqing
since the first confirmed case of new crown pneumonia in late February, Brazil's new crown epidemic continues to spread. Brazil has the second-highest number of deaths from the disease in the world, after the United States.
The Osvaldo Cruz Foundation in Brazil reported in June that genetic studies of the new coronavirus showed that samples of the new coronavirus prevalent in Brazil were similar to samples from Europe, North America and Oceania, indicating the path of the new coronavirus to Brazil. Studying the route of transmission of the virus will help to understand the mutation status of the virus and develop relevant treatment methods.
at the Institute of Biomedical Sciences at the University of Sao Paulo in Brazil have developed a cloth with silver particles that can inactive more than 99 percent of the virus after two minutes of exposure to the new coronavirus. This fabric consists of polyester cotton and silver particles and can be used in the production of masks and protective clothing, etc., a South African correspondent for this newspaper, said
the new coronavirus vaccine in South Africa began Phase I clinical trials. The first phase I clinical trial of the new coronavirus vaccine ChAdOx1 was announced by the University of Kinshan in South Africa on June 23, 2020. The aim of the trial was to see if the vaccine could prevent neo-corona pneumonia, cause unacceptable side effects, and induce a satisfactory immune response. The 150 million rand study is expected to be conducted in metropolitan areas with a high risk of neo-coronavirus infection and likely to be a hot spot for the new coronary pneumonia outbreak.
South African pharmaceutical company Aspen announced on November 2nd that it had reached a preliminary agreement with a subsidiary of Johnson and Johnson, which owns intellectual property rights, to cooperate in the transfer of technology and commercial production of a candidate vaccine for new coronal pneumonia. The vaccine candidate is currently undergoing Phase III. clinical trials and has been included in the World Health Organization's list of 26 most viable vaccine candidates for human clinical trials. Aspen Pharmaceuticals said it will formula, fill and secondary packaging the vaccine and then provide it to Johnson and Johnson. Aspen Group is expected to start production in March or April 2021.This newspaper's correspondent in South Korea, Yu Yu
Korea has developed the "K-Epidemic Prevention" model of international standard guidelines, perfected the "3T" epidemic prevention system covering detection and diagnosis, epidemiological investigation and follow-up, isolation and treatment, and submitted 18 international standard proposals to the International Organization for Standardization in stages.
The Korean research team has jointly identified a key protein that causes cytokine storms and lung damage in patients with neocytosis as a biosynthetic regulatory protein (SREBP) in the body, which is expected to assist in the development of diagnostic and therapeutic drugs for severely ill patients.
a joint study in South Korea has completed the world's first genetic map of ultra-fresh coronary pneumonia virus. Another study showed details of how the new coronary pneumonia virus induces inflammation of blood vessels and reduces the body's immunity. South Korea's National Institutes of Health, the Ministry of Disease Management, said the successful preparation of a new vaccine for coronary pneumonia based on virus-like particles (VLPs).
Korea's Institute of Basic Scientific Support has developed a biosensors technology that can diagnose new coronary pneumonia in a minute by collecting samples from the nasal cavity. The Korea Institute of Chemistry has developed a variety of special antibody manufacturing techniques that bind to new coronavirus antigens, as well as rapid diagnostic techniques for the use of these antibodies. This newspaper's BRITISH correspondent Tian Disciplinary
The British government attaches great importance to the research of new crown vaccines and treatment methods, set up a special agency to promote the development of vaccines to promote, coordinate research and accelerate the production of new crown vaccines, to ensure that vaccines can be used as soon as possible, and in April 2020 set up a special "vaccine task force." The government has also done all it can to speed up the launch of the new crown vaccine, ingesting the green light for vaccine development and clinical trials, making it the first Western country to approve the clinical use of the new crown vaccine.
government has invested heavily in supporting vaccine and drug development. At the start of the outbreak, the UK immediately announced that it would invest 25 million pounds to support research into the new coronavirus. In addition, the Uk government has invested ￡20 million and ￡22.5 million, respectively, in Oxford University and Imperial College London to support its researchers in research and clinical trials of the new coronavirus vaccine. In an effort to take the lead in the international fight against the new coronavirus, the UK has raised a total of ￡744 million to support domestic and international research into vaccines, drugs and treatment technologies.
in the development of new coronary pneumonia drugs, Oxford University led the trial of an anti-inflammatory antimalarial drug to determine whether it can mitigate the impact of the new coronavirus on high-risk populations. It is worth mentioning that for the first time, the British medical community has found that the inexpensive and easily available existing drug, dexamisson, has the special effect of saving the lives of patients with severe neocephal pneumonia and reducing the rate of death.
the UK is one of the world's biggest supporters of the search for a coronavirus vaccine, providing the Centre for Epidemiological Prevention and Innovation with a funding of 250 million pounds for international research into pandemic diseases. The UK is also one of the biggest backers of the World Health Organization and the Global Alliance for Vaccine Immunization (Gavi) and is actively campaigning for the New Coronavirus Global Response Summit and the Global Vaccine Summit. In response to the needs of the outbreak, the Ukrainian government, through the National Research Fund, has launched a "Human Security and Social Sciences" research project to address pressing human security and social issues, especially in areas related to the new coronavirus
. Ukrainian scientists have achieved remarkable results in digital modeling and prediction of the neo-coronavirus pandemic, as well as the successful development of diagnostic mechanisms and therapies for patients with thrombosis complications.
In December 2020, the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine developed a polymerase chain reaction test that can simultaneously detect the presence of new coronavirus and influenza viruses A and B viruses, a combination that takes about six hours to test. Currently, the institute is developing another way to detect five seasonal pandemic viruses simultaneously. This newspaper's japan correspondent Chen Chao
Tohoku University and Shimazu Production Institute in Japan carried out a joint study, developed the use of exhale for non-invasive detection of the exhaled histological analysis system, can replace the previous nasopharyngeal swab detection system. Yokohama City University has successfully developed four anti-medical reagents that detect new coronavirus antibodies. Using a fully automated luminescence enzyme immuno-testing device, up to 240 samples can be detected in 1 hour, further reducing the time to detect results. Hokkaido University confirms that saliva PCR detection accuracy is about 90%, higher than nasopharyngeal swabs.
University in Ryukyu, Japan, confirmed that the gland therapy drug "Aki daffodils" can effectively prevent the seriousness of new coronavirus infection, starting in January 2021 clinical trials. If proven effective against the new coronavirus, it will be the first anti-inflammatory drug for mild and moderate patients. A team of researchers from Kyoto Prefecture Medical University and Osaka University successfully increased the viral binding capacity of the new coronavirus's subject, ACE2 protein, by more than 100 times. The use of high affinity modified ACE2 protein, which improves binding power, is expected to inhibit viral infection of human cells. Osaka University has found that early use of toads to prevent cytokine storms in neocooproid pneumonia is expected to have an effect on the treatment of early pneumonia. The Russian correspondent Dong Yingxuan
Russia is one of the first countries in the world to develop rapid testing reagents, russia's "vector" virology and biotechnology National Science Center in just one week to develop nucleic acid testing reagents. There are now 23 nucleic acid testing reagents and anti-medical reagents approved and used in Russia.
In the development of new crown vaccines, Russia has developed 47 new crown vaccines using 14 technical routes, including RNA vaccines, all-virus inactivated vaccines and recombinated protein vaccines, and WHO has included nine new crown vaccines developed in Russia on its alternative list. The first new crown vaccine, Satellite-V (Adenovirus Vector Vaccine), developed by the Russian National Research Center for Epidemiology and Microbiology, was approved for emergency use and Phase III. EpiVac Corona, the second vaccine developed by the National Science Center for Vector Virology and Biotechnology based on peptide antigens, has been registered;
new crown drug developed by the Russian Direct Investment Fund and the "Shimlal" group company, Avivave, was approved by the Russian Ministry of Health in June, the first approved anti-new crown virus drug in Russia. Three's correspondent in Israel, Mao Li
after the outbreak, Israeli research institutions, medical units and technology companies to give full play to its innovative advantages, rapid development of new coronavirus vaccines and drugs, while seeking new coronavirus patient testing means.
in vaccines, the most prominent was the Brilife new coronavirus vaccine developed by the Israel Institute of Biological Research. The researchers obtained an anti-neovirus vaccine by genetically engineering specific proteins to attach specific proteins to the "crown" of a new coronavirus that forms a new coronavirus on a virus that is harmless to humans.
in terms of drugs and therapies, Prestum Medical has developed placental PLX cell drugs that improve and survive six high-risk new coronavirus patients. Tel Aviv University has confirmed that "cocktail" drugs that use three antibodies at the same time are effective against the new coronavirus, providing natural immunity. Hadassah Medical Center has developed an "anti-neo-coronavirus plasma-derived immunoglobulin (IgG) product" that can be used for practical treatment before the patient recovers and returns home. The Israel Institute of Biological Research has isolated a monoclonal antibody that targets only the new coronavirus and is expected to be a drug in response to the outbreak. The institute also found that two drugs used to treat High Snow's disease were effective against the new coronavirus and could be used as broad-spectrum antiviral therapy in future coronavirus outbreaks.
in virus detection, researchers have developed a small spectral detection method to diagnose new coronavirus infections by detecting spitting mouthwash ultra-quickly, with a 95 percent accuracy in one second. A small, simple new coronavirus detector developed by israel's Polytechnic University uses nanotechnology to analyze the gas exhaled by the tester to identify substances in his lungs and determine whether he or she has been infected with the new coronavirus.